Skip to content
  • Flamingo-01 Phase III
  • GP2 Product
  • Press Releases
  • Email Alerts
Logo of Greenwich LifeSciences.
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY BACKGROUND
  • CLINICAL TRIALS
    • COMPLETED PHASE IIB CLINICAL TRIAL
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY BACKGROUND
  • CLINICAL TRIALS
    • COMPLETED PHASE IIB CLINICAL TRIAL
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT

Contact

Connect With Us!

For press release email alerts, please sign up here.

For general inquiries, please use:

info@greenwichlifesciences.com
(832) 819-3232

For Flamingo-01 Phase III clinical trial inquiries, please use:

flamingo-01@greenwichlifesciences.com
Logo of Greenwich LifeSciences.

Copyright © 2021

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Privacy Policy
Disclaimer
Sitemap
Logo of Greenwich LifeSciences.

Copyright © 2021

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Privacy Policy
Disclaimer
Sitemap